SCHEMBL6514196

SCHEMBL6514196

Cn1c(=O)[nH]c(=O)c2cc(C(=O)O)cnc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
HPGD P15428 3/20 0.58
LMNA P02545 3/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 2/20 0.45
MEN1 O00255 1/20 0.45
PABPC1 P11940 1/20 0.45
CYP3A4 P08684 1/20 0.45
PMP22 Q01453 1/20 0.45
ALDH1A1 P00352 4/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.38
PARP1 P09874 1/20 0.35
CSNK2A1 P68400 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
EEF2K O00418 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7145632 0.76 ALDH1A1 (0.60) KDM4EHPGDLMNAKMT2AMAPK1
SCHEMBL15331229 0.75 MAPK1 (0.46) KDM4EHPGDLMNAKMT2AMAPK1
SCHEMBL6243935 0.73 KDM4E (0.56) KDM4EHPGDKMT2AALDH1A1PARP1
SCHEMBL17824568 0.72 LMNA (0.48) KDM4EHPGDLMNAKMT2AMAPK1
SCHEMBL6240235 0.71 KMT2A (0.41) KDM4EHPGDLMNAKMT2AMAPK1
SCHEMBL18255833 0.70 CYP3A4 (0.47) KDM4EHPGDLMNAKMT2AMAPK1
SCHEMBL7214662 0.68 GRM5 (0.55) KDM4EHPGDLMNAKMT2AALDH1A1
SCHEMBL5070874 0.68 SPR (0.61) HPGDLMNAMAPK1MAPTL3MBTL1
SCHEMBL17963082 0.68 HCAR2 (0.40) KDM4EALDH1A1L3MBTL1HSD17B10POLB
SCHEMBL6517346 0.67 ALDH1A1 (0.56) KDM4EHPGDLMNAKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 KDM4E 1784/4885HPGD 228/4885LMNA 3812/4885
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 KDM4E 2484/4885HPGD 397/4885LMNA 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.